Protagonist Therapeutics / BeOne Medicines: Day 1 EHA: All For Degrader Good – We Continue to View BGB-16673 and Rusfertide as Differentiated Assets

Research evidence excerpt

Protagonist Therapeutics / BeOne Medicines: Day 1 EHA: All For Degrader Good – We Continue to View BGB-16673 and Rusfertide as Differentiated Assets

Equity Research

12 June 2026

Protagonist Therapeutics / BeOne Medicines

Day 1 EHA: All For Degrader Good –

We Continue to View BGB-16673

PTGX OVERWEIGHTand Rusfertide as Differentiated

U.S. Small & Mid Cap POSITIVE BiotechnologyAssets Price Target USD 119.00

Price (10-Jun-26) USD 105.77

Nurix presented updated data from its BTK degrader in R/R Potential Upside/Downside +12.5%

CLL, and Silence presented updated data from divesiran in Source: Bloomberg, Barclays Research

PV; bottom line, we continue to view the data to date from ONC OVERWEIGHT

U.S. Small & Mid CapBGB-16673 and Rusfertide as differentiated. POSITIVE Biotechnology

Price Target USD 409.00

Price (10-Jun-26) USD 263.61

Potential Upside/Downside +55.2%

Source: Bloomberg, Barclays Research

THE EXTEL SURVEY IS CLOSING SOON

U.S. Small & Mid Cap Biotechnology

Support our industry-leading Etzer Darout, PhD, MBA

analysts with 5-Star votes in +1etzer.darout@barclays.com212 526 6940

the 2026 Extel All-America BCI, US

Research Survey. Jordan+1 212 526Becker,3960PhD

jordan.becker1@barclays.com

BCI, US

Vote Now View Analysts

Lukas Shumway, PhD

+1 212 526 7293

lukas.shumway@barclays.com

BCI, USThe following listed companies are not under coverage by Barclays Research: Nurix Therapeutics,

Silence Therapeutics. Information about these companies is being provided for information Gustave Diep, MD

purposes only and is not an investment recommendation by Barclays Research. +1 212 526 0347

gustave.diep@barclays.com

Both Silence Therapeutics (not covered, poster) and Nurix (not covered, press release) BCI, US